Between 62 % and 67 % of US adults with a history of CHD, MI and stroke were estimated to be recommended add-on lipid-lowering therapy and between 2.9 % and 4.0 % of these populations were taking ezetimibe or a PCSK9 inhibitor. The gene discussed is PCSK9; the disease is stroke disorder.